Introduction

The biotech industry features innovative companies with strong growth potential, but their pipeline strengths often vary. This article evaluates and ranks the pipelines of four biotech companies—Arvinas (ARVN), Catalyst Pharmaceuticals (CPRX), ADC Therapeutics (ADCT), and Mirum Pharmaceuticals (MIRM)—using a scoring system based on their product development stages.

Scoring System

Each development stage is assigned a weighted score to reflect its value and reduced risk:

• Approved Products: 4 points each
• Phase 3: 3 points each
• Phase 2: 2 points each
• Phase 1: 1 point each

Pipeline Overview and Scores

1. Arvinas (ARVN)

• Approved Products: 0
• Phase 3: 1 (Vepdegestrant for ER+/HER2- breast cancer)
• Phase 2: 1 (Bavdegalutamide for metastatic prostate cancer)
• Phase 1: 2 (ARV-766 and ARV-102)

Total Score: 7 points

2. Catalyst Pharmaceuticals (CPRX)

• Approved Products: 3 (Firdapse, Fycompa, Agamree)
• Phase 3: 0
• Phase 2: 0
• Phase 1: 0

Total Score: 12 points

3. ADC Therapeutics (ADCT)

• Approved Products: 1 (Zynlonta)
• Phase 3: 0
• Phase 2: 1 (Camidanlumab tesirine)
• Phase 1: 2 (ADCT-602 and ADCT-601)

Total Score: 8 points

4. Mirum Pharmaceuticals (MIRM)

• Approved Products: 1 (LIVMARLI)
• Phase 3: 0
• Phase 2: 1 (Volixibat)
• Phase 1: 0

Total Score: 6 points

Final Rankings

1. Catalyst Pharmaceuticals (CPRX): 12 points
2. ADC Therapeutics (ADCT): 8 points
3. Arvinas (ARVN): 7 points
4. Mirum Pharmaceuticals (MIRM): 6 points

Catalyst Pharmaceuticals ranks highest due to its portfolio of approved products, while ADC Therapeutics, Arvinas, and Mirum follow based on their pipeline stages and innovation.